Not likely any approval before the cash runs out. HIV has virtually no chance of approval before 2023, NASH and oncology is going to be years away, CoV low likelihood of any 2022 approvals.
The biggest problem is no cash to get the clinical data for the BLA, no cash for any further trials, so not likely to have any revenue in the company's lifetime.
The race is who takes the company down first -- bankruptcy court or SEC and DOJ action. Not a pretty scenario.
Market Data 
Markets 
AI
